Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant cabazitaxel + cisplatin for muscle-invasive bladder cancer
2011-004090-82Phase 2Unknown
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Feb 2012
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel and cisplatin in bladder cancer, sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Pathological response rate. Status: unknown.
02
Drugs
cabazitaxelcisplatin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2011-004090-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004090-82.